A trial by AIIMS shows digoxin may reduce worsening heart failure in rheumatic heart disease patients, offering a low-cost treatment option.

Digoxin, a cardiac glycoside derived from the foxglove plant, has been a mainstay of treatment in systolic heart failure and in rate control for atrial fibrillation. By inhibiting the cardiac ...

The drug is derived from the foxglove plant (Digitalis purpurea), which was first described as a treatment for “dropsy” — now ...

UB researchers have identified for the first time an enzyme in the foxglove plant that is responsible for the production of compounds needed to make the heart failure drug digoxin. The breakthrough ...

India: A new study has found that among patients with symptomatic rheumatic heart disease, digoxin was associated with a ...

Digoxin now deserves to be considered first-line therapy for long-term heart rate control in older patients with permanent atrial fibrillation and symptoms of heart failure, investigators on a new ...

Digitalis glycosides may be a safe and tolerable addition to optimal guideline medical therapy to reduce worsening heart ...

"In the DIG trial, published in 1997, digoxin had a neutral effect on the primary endpoint of mortality, but a 28% reduction in heart failure hospitalizations (a secondary endpoint) was observed.

Oct. 30, 2002 — Digoxin may pose a risk of death for women with heart failure, according to a retrospective analysis published in the Oct. 31 issue of the New England Journal of Medicine. Yet ...

A 240-year-old drug called digoxin could save the National Health Service (NHS) at least £100 million each year when treating older patients with atrial fibrillation and heart failure. This was ...

At present, digoxin should not be recommended for the treatment of patients with mild-to-moderate diastolic HF with preserved LVEF of greater than 45% in sinus rhythm This was an ancillary study ...